alpelisib
1. Basic Product Identification
INN Name: Alpelisib
Brand Name: Piqray
Therapeutic Class: PI3K inhibitor (PI3Kα selective)
Route: Oral (tablet)
Target Therapy Area: Oncology (breast cancer)
Primary indication:
HR-positive HER2-negative breast cancer with PIK3CA mutation
2. Therapeutic Knowledge
Alpelisib is used in:
Advanced/metastatic breast cancer
Always in combination with fulvestrant
For PIK3CA-mutated tumors only
Key concept:
???? First-in-class PI3Kα isoform-specific targeted therapy
3. Mechanism of Action (MOA)
Alpelisib selectively inhibits PI3K alpha (PI3Kα).
Pathway:
Blocks PI3K → AKT → mTOR signaling cascade
Effects:
↓ tumor cell proliferation
↓ survival signaling
Induces apoptosis in PIK3CA-mutant cancer cells
Key insight:
???? Targets driver mutation pathway in oncogenesis
4. Pharmacokinetics (ADME)
Absorption
Oral bioavailability moderate
Food has minimal clinically significant effect
Distribution
Moderate plasma protein binding (~80%)
Metabolism
Primarily hepatic metabolism (CYP3A4 involvement minor)
Excretion
Fecal (major)
Urinary (minor)
Half-life:
~8–9 hours
5. Dosage & Administration
Standard regimen:
300 mg once daily (oral tablet)
Combination:
Always with fulvestrant (endocrine therapy)
Administration rules:
Take with food
Same time daily
Dose reduction required in toxicity (hyperglycemia management)
6. Formulation Knowledge
Dosage form:
Film-coated oral tablets
Key formulation challenges:
Low solubility
High-dose strength (oncology dosing)
Stability in humid environments
Technologies used:
Solid dispersion
Particle size reduction
Film coating for stability
7. Raw Materials Knowledge
API:
Alpelisib (synthetic small molecule kinase inhibitor)
Excipients:
Microcrystalline cellulose
Mannitol
Sodium starch glycolate
Magnesium stearate
Film coating polymers (HPMC-based)
Critical issues:
Control of polymorphism
Impurity control (genotoxic impurity risk monitoring)
8. Manufacturing Process Knowledge
API synthesis:
Multi-step heterocyclic organic synthesis
Kinase inhibitor scaffold construction
Purification via crystallization & chromatography
Tablet manufacturing:
Blending (API + excipients)
Dry granulation preferred (stability)
Compression
Film coating
Critical controls:
Uniformity (high-dose oncology tablet)
Impurity profile control (ICH Q3A/Q3B strict)
9. Analytical & QC Knowledge
Key QC tests:
HPLC assay
Impurity profiling (trace-level sensitivity)
Dissolution testing (biorelevant media)
Content uniformity
Water content (KF)
Residual solvents (GC)
Advanced techniques:
LC-MS/MS for impurity tracking
Stability-indicating methods
10. Regulatory Knowledge
Approval status:
FDA approved (targeted oncology indication)
EMA approved
Regulatory requirements:
Companion diagnostic required (PIK3CA mutation test)
Oncology clinical trial package (Phase I–III)
Risk management plan (RMP)
Labeling requirements:
Severe hyperglycemia warning
Rash and pneumonitis risk
Embryo-fetal toxicity warning
11. Storage & Stability
Store at 20–25°C
Protect from moisture
Shelf life: ~24 months
Stability risks:
Humidity-induced degradation
Polymorphic changes
Photostability generally acceptable
12. Packaging Knowledge
Alu-Alu blister packs (moisture protection)
High-barrier HDPE bottles (some markets)
Oncology safety packaging (child-resistant optional but common)
13. Safety & Toxicology
Common adverse effects:
Hyperglycemia (dose-limiting)
Rash
Diarrhea
Fatigue
Nausea
Serious risks:
Severe hyperglycemia → ketoacidosis risk
Pneumonitis
Severe hypersensitivity reactions
Monitoring:
Blood glucose (mandatory)
HbA1c baseline & follow-up
14. Market & Commercial Knowledge
Market type:
Precision oncology / targeted therapy market
Competition:
Endocrine therapy combinations
CDK4/6 inhibitors (different pathway)
Other PI3K inhibitors (limited due to toxicity issues)
Key driver:
Companion diagnostic-based prescription model
15. Intellectual Property (IP)
Strong composition-of-matter patent (Novartis origin)
Companion diagnostic exclusivity supports lifecycle extension
Secondary patents:
Combination therapy
Specific dosing regimens
16. Environmental & EHS Knowledge
Potent cytotoxic/oncology handling precautions
API manufacturing requires containment systems
Waste:
Genotoxic waste classification possible
Worker safety:
Closed-system handling recommended
17. Export Documentation Knowledge
Required:
DMF (Type II API)
GMP certificate (high-potency API compliance)
COA (batch release)
Stability studies (ICH Q1A)
Genotoxic impurity assessment
Bioequivalence study (generic)
MSDS (cytotoxic handling guidance)
18. Business Development Knowledge
Opportunities:
Oncology hospital supply chains
Precision medicine oncology programs
Emerging markets oncology expansion
Strategy:
Partner with diagnostic labs (mutation testing)
Oncology specialist physician networks
Value-based pricing (high-cost therapy)
19. Advanced Technical Knowledge
PI3K pathway is central to tumor survival signaling
Mutation-specific therapy = precision oncology model
Resistance mechanisms include pathway reactivation
Hyperglycemia mechanism linked to insulin signaling interference
Narrow therapeutic index in real-world use
20. AI & Digital Knowledge (Modern Pharma)
AI applications:
Companion diagnostic prediction models
Oncology response prediction (mutation-driven ML models)
Real-world evidence (RWE) tracking
Pharmacovigilance signal detection (hyperglycemia risk patterns)
Digital pharma:
Genomic-guided prescription platforms
Hospital oncology decision-support systems
21. Sales Team Product Knowledge Checklist
Sales teams must know:
Only for PIK3CA-mutated Global alpelisib API Manufacturer in Brussels breast cancer
Always combined with fulvestrant
Blood glucose monitoring requirement
High toxicity management importance
Companion diagnostic necessity
22. Most Important Technical Documents
DMF (API + formulation)
Clinical trial data (SOLAR-1 study)
Companion diagnostic validation reports
Stability studies (ICH Q1A)
Impurity profiling (ICH Q3A/B)
Genotoxicity assessment
Risk Management Plan (RMP)
GMP certificate
23. Ultimate Pharma Product Mastery Summary
Alpelisib is:
A precision oncology PI3Kα inhibitor
Technically complex due to:
High-dose oral formulation
Toxicity management (hyperglycemia)
Commercially advanced due to:
Companion diagnostic-driven therapy
High-value oncology market
Clinically important in:
Mutation-driven breast cancer treatment